Clinical validation of the Dry Blood Spot (DBS) method for risperidone, aripiprazole, pipamperone and its major metabolites

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON28955

Enrollment

Registered

2017-08-29

Start date

2016-06-09

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

antipsychotics, pipamperone, aripiprazole, paliperidone, risperidone

Interventions

Participants will undergo one fingerprick and venipuncture which will cause mild local irritation.

Eligibility

Inclusion criteria

Inclusion criteria: - using either aripiprazole, risperidone, paliperidone or pipamperone - ≥ 18 years

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
The main study parameter is the agreement between antipsychotic drug plasma levels of blood collected by venipuncture or DBS, both measured by ultra-performance liquid chromatography tandem mass-spectrometry (UHPLC-MS/MS)	—

Secondary

Measure	Time frame
Covariates influencing through levels	—

Contacts

Public ContactB.C.P. Koch

Erasmus Medical Centre - Department of Hospital Pharmacy

b.koch@erasmusmc.nl+31(0)10-7040704

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)